Genetic Variants Help Explain Who Benefits Most from GLP-1 Weight-Loss Drugs
Updated
Updated · ScienceDaily · Apr 12
Genetic Variants Help Explain Who Benefits Most from GLP-1 Weight-Loss Drugs
53 articles · Updated · ScienceDaily · Apr 12
New studies reveal that genetic differences can significantly influence how well people respond to popular GLP-1 weight-loss drugs like Ozempic and Mounjaro.
Variants in genes such as GLP1R and GIPR affect both the amount of weight lost and the likelihood of side effects like nausea and vomiting.
These findings may pave the way for more personalised obesity treatments, though other factors such as age, sex, and underlying health remain important.
How might these genetic discoveries shape insurance coverage or access to GLP-1 drugs for people from diverse backgrounds?
Could behavioral 'microsteps' combined with GLP-1s be the real key to lasting weight loss, beyond what genes predict?
How can healthcare providers ensure safe GLP-1 use amid rising dosing errors and complex genetic risk profiles?
If genetic risk is higher in some ancestries, could current drug guidelines unintentionally leave others behind?
Will future obesity treatments blend genetic testing with AI-powered lifestyle coaching for truly customized care?
Personalized GLP-1 Therapy: Genetic Insights Drive Weight Loss Outcomes and Side Effect Risks
Overview
A 2026 genome-wide study by 23andMe identified key genetic variants in GLP1R and GIPR genes that influence how individuals respond to GLP-1 drugs like semaglutide and tirzepatide, affecting both weight loss and side effect risks. These genetic insights, combined with factors like age, sex, and drug type, enabled 23andMe to develop predictive models and an interactive tool that helps personalize treatment decisions. Clinical trials confirmed these drugs also reduce cardiovascular and kidney risks, leading to FDA approvals. Despite promising advances, challenges such as side effects, ethical concerns, and healthcare disparities remain, highlighting the need for ongoing research and equitable implementation to fully realize precision obesity medicine.